Literature DB >> 31183589

Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.

Mari Aoe1, Takafumi Kanemitsu1, Takamasa Ohki1, Satoru Kishi1, Yoshiyasu Ogura1, Yuto Takenaka1, Toyohiro Hashiba1, Hiroko Ambe1, Emi Furukawa1, Yu Kurata1, Masahiro Ichikawa1, Ken Ohara1, Tomoko Honda1, Satoshi Furuse1, Katsunori Saito1, Nobuo Toda1, Naobumi Mise2.   

Abstract

BACKGROUND: Transcatheter arterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC). The purpose of this study was to investigate incidence and risk factors of contrast-induced nephropathy (CIN) after TACE in patients with HCC.
METHODS: In this single-center retrospective study, we examined 461 consecutive TACE sessions in 260 patients between January 2003 and October 2015. CIN was defined as an increase in serum creatinine levels by ≥ 0.5 mg/dl or ≥ 25% from baseline within 72 h after TACE. We calculated incidence rate of CIN and tried to identify its risk factors by logistic regression analysis.
RESULTS: Twenty-one cases of CIN (5%) were observed in 461 TACE sessions. One patient required subsequent hemodialysis transiently. In univariate analysis, tumor size > 5 cm [odds ratio (OR) 5.76, 95% confidence interval (CI) 2.34-14.14, p < 0.001], chronic kidney disease (OR 2.54, 95% CI 1.05-6.14, p = 0.04), serum hemoglobin level [OR 0.79 (per 1 g/dl increase), 95% CI 0.64-0.98, p = 0.03] and serum albumin level [OR 0.44 (per 1 g/dl increase), 95% CI 0.19-1.02, p = 0.05] were associated with the development of CIN. Stepwise logistic regression methods showed that tumor size > 5 cm (OR 7.81, 95% CI 2.99-20.46, p < 0.001) and serum albumin [OR 0.29 (per 1 g/dl increase), 95% CI 0.11-0.75, p = 0.01] were risk factors of CIN.
CONCLUSIONS: In this study, HCC tumor size and lower serum albumin level were independent predictors of CIN after TACE.

Entities:  

Keywords:  Contrast-induced nephropathy (CIN); Hepatocellular carcinoma (HCC).; Transarterial chemoembolisation (TACE)

Mesh:

Substances:

Year:  2019        PMID: 31183589     DOI: 10.1007/s10157-019-01751-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  21 in total

Review 1.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

2.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Chung-Mau Lo; Henry Ngan; Wai-Kuen Tso; Chi-Leung Liu; Chi-Ming Lam; Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

3.  Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.

Authors:  Hyun Seop Cho; Jong Woo Seo; Yeojin Kang; Eun Jin Bae; Hyun-Jung Kim; Se-Ho Chang; Dong Jun Park
Journal:  Clin Exp Nephrol       Date:  2011-06-23       Impact factor: 2.801

4.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

5.  Acute kidney injury after transarterial chemoembolization for hepatocellular carcinoma: a retrospective analysis.

Authors:  Jongha Park; Hyun Chul Chung; Jong Soo Lee; Byeong Man Lee; Dong Min Kim; Jae Cheol Hwang; Min-Woo Jo; Maengseok Noh; Jung Woo Shin
Journal:  Blood Purif       Date:  2008-09-22       Impact factor: 2.614

6.  Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome.

Authors:  T-I Huo; J-C Wu; Y-H Huang; J-H Chiang; P-C Lee; F-Y Chang; S-D Lee
Journal:  Aliment Pharmacol Ther       Date:  2004-05-01       Impact factor: 8.171

7.  [Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].

Authors:  Byoung Kuk Jang; Seung Hyun Lee; Woo Jin Chung; Kyung Sik Park; Kwang Bum Cho; Jae Seok Hwang; Young Hwan Kim; Jin Soo Choi; Jung Hyeok Kwon
Journal:  Korean J Hepatol       Date:  2008-06

8.  Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study.

Authors:  Teh-Ia Huo; Jaw-Ching Wu; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  Liver Int       Date:  2004-06       Impact factor: 5.828

9.  Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency.

Authors:  Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Jen-Huey Chiang; Han-Chieh Lin; Pui-Ching Lee; Fa-Yauh Lee; Teh-Ia Huo; Shou-Dong Lee
Journal:  J Clin Gastroenterol       Date:  2010-09       Impact factor: 3.062

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more
  2 in total

1.  Association between chronic kidney disease and cancer including the mortality of cancer patients: national health and nutrition examination survey 1999-2014.

Authors:  Kanglin Guo; Zufeng Wang; Ran Luo; Yichun Cheng; Shuwang Ge; Gang Xu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

2.  Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?

Authors:  Lukas Müller; Felix Hahn; Aline Mähringer-Kunz; Fabian Stoehr; Simon J Gairing; Friedrich Foerster; Arndt Weinmann; Peter R Galle; Jens Mittler; Daniel Pinto Dos Santos; Michael B Pitton; Christoph Düber; Roman Kloeckner
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.